Mucinous tumors of the ovary: Current thoughts on diagnosis and management

Current Oncology Reports

Volumn 16, Issue 6, 2014, Pages

  Brown, Jubilee ^a   Frumovitz, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Borderline; Carcinoma; Gynecologic cancer; Gynecologic cancers; Mucinous; Mucinous ovarian tumors; Mucinous tumor; Neoplasm; Oncology; Ovary; Pseudomyxoma; Tumor

Indexed keywords

K RAS PROTEIN; PROTEIN P53; TUMOR MARKER; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER SURGERY; CLINICAL FEATURE; CYSTADENOMA; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MUCINOUS OVARY TUMOR; OVARY TUMOR; PATHOGENESIS; PATHOPHYSIOLOGY; SYMPTOM; COLLOID CARCINOMA; DISEASE MANAGEMENT; FEMALE; GENETICS; REVIEW;

ADENOCARCINOMA, MUCINOUS; ANTINEOPLASTIC AGENTS; CYSTADENOMA, MUCINOUS; DISEASE MANAGEMENT; FEMALE; HUMANS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901289256     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-014-0389-x     Document Type: Article

References (63)

1. Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010;117:491-6.
2. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040-4. (Pubitemid 41095036)
3. Mondal SK, Banyopadhyay R, Nag DR, et al. Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: a 10-year study in a tertiary hospital in eastern India. J Cancer Res Ther. 2011;4:433-7.
4. Koonings PP. Relative frequencies of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989;74:921-6. (Pubitemid 20003288)
5. Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26:1529-41. (Pubitemid 35387217)
6. Chiesa AG, Deavers MT, Veras E, et al. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? Int J Gynecol Pathol. 2010;29:108-12.
7. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
8. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinoma in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985-93. (Pubitemid 36763545)
9. Shimada M, Kigawa J, Ohishi Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2009;113:331-4.
10. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IVovarian cancer. N Engl J Med. 1996;334:1-6. (Pubitemid 26012496)
11. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophos- phamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699-708. (Pubitemid 30365530)
12. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IVovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000;18:106-15. (Pubitemid 30036343)
13. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419-25.
14. Hart WR, Norris HJ. Borderline and malignant mucinous tumours of the ovary: histologic criteria and clinical behavior. Cancer. 1973;31: 1031-45.
15. Lack EE, Young RH, Scully RE. Pathology of ovarian neoplasms in childhood and adolescence. Pathol Annu. 1992;27:281-356.
16. Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol. 1999;23:617-35. (Pubitemid 29262825)
17. Tait DL, Miller DS. Multicystic ovarian tumor weighing 156 lbs: the second largest tumor in Texas. Tex Med. 1997;93:89.
18. Chao A, Chao A, Yen YS, Huang CH. Abdominal compartment syndrome secondary to ovarian mucinous cystadenoma. Obstet Gynecol. 2004;104:1180-2.
19. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27:281-92. (Pubitemid 36245793)
20. Boger-Megiddo I, Weiss NS. Histologic subtypes and laterality of primary epithelial ovarian tumors. Gynecol Oncol. 2005;97:80-3. (Pubitemid 40403678)
21. Khunamornpong S, Suprasert P, Pojchamarnwiputh S, et al. Primary and metastatic mucinous adenocarcinomas of the ovary: evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol. 2006;101:152-7.
22. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41-4. (Pubitemid 38018236)
23. Cho YH, Kim DY, Kim JH, et al. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors? Gynecol Oncol. 2006;103:878-82.
24. Roger N, Zafrani Y, Uzan C, et al. Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer? Ann Surg Oncol. 2008;15:333-8.
25. Schmeler KM, Tao X, Frumovitz M, et al. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010;116:269-73.
26. Leblanc E, Querleu D, Narducci F, et al. Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience. Gynecol Oncol. 2004;94:624-9. (Pubitemid 39194452)
27. Tholander B, Taube A, Lindgren A, et al. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol. 1990;39:26-33. (Pubitemid 20378255)
28. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215-45.
29. Nolen B, Marrangoni A, Velikokhatnaya L, et al. A serum based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol. 2009;112:47-54.
30. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 2008;108:276-81.
31. Fleming GF, Ronnett BM, Seidman J, et al. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, editors. Principles and practice of gynecologic oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 763-835.
32. NCCNGuidelines - Ovarian Cancer, Version 2.2013, accessed on 10/1/2013.
33. Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002;87:1-7. (Pubitemid 36027095)
34. Wright JD, Shah M, Mathew L, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer. 2009;115:4118-26.
35. Gershenson DM. Treatment of ovarian cancer in young women. Clin Obstet Gynecol. 2012;55:65-74.
36. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'Pseudomyxoma Peritonei'. Am J Surg Pathol. 2000;24:1447-64.
37. Lin JE, Seo S, Kushner DM, Rose SL. The role of appendectomy for mucinous ovarian neoplasms. Am J Obstet Gynecol. 2013;208: 46e1-4.
38. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20: 1248-59. (Pubitemid 34177431)
39. Naik JD, Seligman J, Perren TJ.Mucinous tumors of the ovary. J Clin Pathol. 2012;65:580-4.
40. Link Jr CJ, Reed E, Sarosy G, et al. Borderline ovarian tumors. Am J Med. 1996;101:217-25.
41. Leys CM, Gasior AC, Hornberger LH, St. Peter SD. Laparoscopic resection of massive ovarianmucinous cystadenoma. J Laparoendosc Adv Surg Tech. 2012;22:307-10.
42. Eltabbakh GH, Charbonneau AM, Eltabbakh NG. Laparoscopic surgery for large benign ovarian cysts. Gynecol Oncol. 2008;108: 72-6. (Pubitemid 350299424)
43. Ji J, Forsti A, Sundquist J, Lenner P, Hemminki K. Survival in ovarian cancer patients by histology and family history. Acta Oncol. 2008;47:1133-9.
44. Winter III WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-7. (Pubitemid 47372600)
45. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005;97:436-41. (Pubitemid 40614887)
46. Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer. 2008;8:252.
47. Rodriguez IM, Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol. 2002;26:139-52. (Pubitemid 34127494)
48. Ronnett BM, Yemelyanova AV, Vang R, et al. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. AmJ Surg Pathol. 2008;32:1835-53.
49. Cao D, Ji H, Ronnett BM. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol. 2005;24:67-72. (Pubitemid 40066455)
50. Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol. 2009;36:8-37.
51. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-9. (Pubitemid 19213607)
52. Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 2003;90:378-81. (Pubitemid 36952030)
53. Mok SC, Bell DA, Knapp RC, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 1993;53:1489-92. (Pubitemid 23113216)
54. Tonin PN, Maugard CM, Perret C, Mes-Masson AM, Provencher DM. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. Fam Cancer. 2007;6:491-7. (Pubitemid 47622264)
55. Evans DG, Young K, Bulman M, et al. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families. Clin Genet. 2008;73:338-45. (Pubitemid 351386993)
56. Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat. 2003;21:285-91. (Pubitemid 36292970)
57. Marchini S,Mariani P, Chiorino G, et al. Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res. 2008;14:7850-60.
58. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, et al. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer. 2006;94:904-13.
59. Sarrio D, Moreno-Bueno G, Sanchez-Estevez C, et al. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol. 2006;37:1042-9. (Pubitemid 44080810)
60. Brun JL, Cortez A, Commo F, Uzan S, Rouzier R, Darai E. Serous and mucinous ovarian tumors express different profiles of MMP-2, - 7, -9,MT1-MMP, and TIMP-1 and -2. Int J Oncol. 2008;33:1239-46.
61. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoSMed. 2008;5:e232.
62. Matsuo K,MasatoM, NishimuraM, et al. Targeting Src in mucinous ovarian carcinoma. Clin Cancer Res. 2011;17:5367-78.
63. Sato S, Itamochi H, Kigawa J, et al. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci. 2009;100:546-51.